Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain

Last updated: April 2, 2025
Sponsor: Boston Scientific Corporation
Overall Status: Active - Recruiting

Phase

N/A

Condition

Chronic Pain

Treatment

Intracept™ Intraosseous Nerve Ablation

Clinical Study ID

NCT06827262
REL025
  • Ages > 18
  • All Genders

Study Summary

Compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Study candidate is scheduled to be treated with a commercially approved Intracept™Intraosseous Nerve Ablation System per local Instructions for Use (IFU).

  • Signed a valid, IRB/EC-approved informed consent form.

Exclusion

Exclusion Criteria:

  • Meets any contraindications per locally applicable Instructions for Use (IFU).

Study Design

Total Participants: 1500
Treatment Group(s): 1
Primary Treatment: Intracept™ Intraosseous Nerve Ablation
Phase:
Study Start date:
March 26, 2025
Estimated Completion Date:
July 31, 2034

Study Description

The objective of this study is to compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.

Connect with a study center

  • MarinHealth Spine Institute

    Larkspur, California 94939
    United States

    Active - Recruiting

  • Pacific Sports and Spine

    Eugene, Oregon 97404
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.